AVA NewTechnology

AVA NewTechnology

At AVA NewTechnology, we are laying the foundation for groundbreaking precision medical diagnostic-, and therapy technologies with a focus on hemato-oncological diseases.
The first big success of AVA NewTechnology is the development of our proprietary NextGenMonoclonals® platform. It allows the identification of unique monoclonal antibodies (mAbs) of the highest specificity for use in precision medicine.
With the NextGenMonoclonals® platform, we are focusing on precision medical approaches, acting as spearhead in the establishment of efficient haemato-oncological companion diagnostics (CDx).



Activities of AVA LifeScience

Currently, we concentrate on B-cell-associated diseases with a focus on aggressive forms of CLL. We have expanded our scope with projects dealing with other B cell-associated diseases (e.g. diffuse large cell B-cell lymphoma).

Our explicit goal for the future is the development of specific mABs against autoimmune diseases, e.g. Multiple Sclerosis or Rheumatoid Arthritis.


Exceptional possibilities through unsurpassed precision.

The first product of the NextGenMonoclonals® platform is AVA-mAb01, which opens up a completely new world for targeted therapies with its exceptional tumor specificity.
AVA mAb01 is directed against a specific surface structure present on malignant B-cells of an aggressive chronic lymphocytic leukemia (CLL) form. Due to its high accuracy, AVA mAb01 allows not only stratified pharmacotherapy but also the establishment of an innovative companion diagnostics.